Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NT 201 Clear all
Completed Phase 2 Interventional

Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery

NCT01842529
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation, Indications for CABG
Interventions
botulinum toxin injection, 0.9% normal saline injection, Implantable loop recorder
Biological · Device
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines

NCT04249687
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Manhattan Beach, California • San Diego, California • Solana Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 5:55 AM EDT
Recruiting Phase 2 Interventional

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT07553065
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham
Combination Product
Lead sponsor
Vensica Therapeutics Ltd.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Margate, Florida • Pompano Beach, Florida • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

The Treatment of Glabellar Frown Lines

NCT02096081
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA, OnabotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Phase 2 Interventional Results available

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

NCT04965311
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

NCT06604832
View directory record Official record
Conditions
Skin Aging, Skin Wrinkling
Interventions
PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo)
Drug
Lead sponsor
Kalpna Kay Durairaj, MD, FACS
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

NCT04594213
View directory record Official record
Conditions
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Encino, California • Newport Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 23, 2026, 5:55 AM EDT
Recruiting Phase 2 Interventional

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

NCT07486830
View directory record Official record
Conditions
Provoked Vestibulodynia
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00770211
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 23, 2026, 5:55 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles

NCT02019004
View directory record Official record
Conditions
Wrinkles
Interventions
Onabotulinum Toxin A, Incobotulinum Toxin A
Drug
Lead sponsor
Northwestern University
Other
Eligibility
20 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Glabellar Lines

NCT04249583
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Manhattan Beach, California • Vista, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

NCT00770029
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

NCT01931878
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
incobotulinumtoxinA, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

NCT01464307
View directory record Official record
Conditions
Post-stroke Spasticity of the Lower Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

NCT02677805
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo, Botulinum Toxin A - Open Label
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 23, 2026, 5:55 AM EDT
Completed No phase listed Observational

Blepharospasm Patient Survey for Patients With Blepharospasm

NCT01686061
View directory record Official record
Conditions
Blepharospasm
Interventions
No intervention- only one time survey
Other
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 81 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Fountain Valley, California • Sarasota, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis

NCT04148872
View directory record Official record
Conditions
Synkinesis
Interventions
Neuromuscular Retraining Therapy (4 months), Chemodenervation (4 months), Neuromuscular Retraining + Chemodenervation
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

NCT01603459
View directory record Official record
Conditions
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

NCT01392300
View directory record Official record
Conditions
Post-stroke Spasticity of the Upper Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Downey, California • Fountain Valley, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 23, 2026, 5:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

NCT02419313
View directory record Official record
Conditions
Parkinson, Tremor
Interventions
incobotulinumtoxinA, Saline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity

NCT00945295
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
Botulinum toxin type A, BoNT-A, Rehabilitation Therapy
Drug · Other
Lead sponsor
JoAnn Harnar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 23, 2026, 5:55 AM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 23, 2026, 5:55 AM EDT